Published in Risk Anal on July 01, 2012
Cost-effectiveness of follow-up of pulmonary nodules incidentally detected on cardiac computed tomographic angiography in patients with suspected coronary artery disease. Circulation (2014) 1.44
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer (2008) 1.26
Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models. Risk Anal (2012) 1.09
Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer (2014) 1.08
Chapter 13: CISNET lung models: comparison of model assumptions and model structures. Risk Anal (2012) 0.95
Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control. Risk Anal (2012) 0.94
Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology (2014) 0.88
Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis. Cancer (2015) 0.77
Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study. BMJ Open (2016) 0.75
Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach. PLoS One (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med (2005) 16.70
Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst (1981) 5.59
Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw (2006) 2.82
Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst (2006) 2.66
Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. Cancer Res (2003) 2.48
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiol Biomarkers Prev (2005) 1.83
Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up Studies using a multistage carcinogenesis model. Cancer Causes Control (2007) 1.76
Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population. Risk Anal (2012) 1.74
Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Anal (2012) 1.31
Calibration of disease simulation model using an engineering approach. Value Health (2009) 1.27
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer (2008) 1.26
Chapter 13: CISNET lung models: comparison of model assumptions and model structures. Risk Anal (2012) 0.95
Chapter 15: Impact of tobacco control on lung cancer mortality in the United States over the period 1975-2000--summary and limitations. Risk Anal (2012) 0.81
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol (2004) 7.45
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol (2008) 5.61
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology (2003) 5.42
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res (2004) 5.23
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet (2004) 4.99
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med (2012) 4.72
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res (2010) 4.51
Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol (2003) 4.50
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA (2004) 4.36
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
Small-cell lung cancer. Lancet (2005) 3.98
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ (2014) 3.90
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol (2007) 3.50
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol (2010) 2.97
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol (2005) 2.88
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care (2005) 2.75
Paraesophageal hernias: operation or observation? Ann Surg (2002) 2.71
Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst (2002) 2.71
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol (2008) 2.69
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res (2006) 2.68
Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 2.62
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 2.53
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol (2008) 2.51
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Utilization of diagnostic medical imaging: comparison of radiologist referral versus same-specialty referral. Radiology (2007) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res (2007) 2.45
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37